Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06646289) titled 'A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)' on Oct. 16, 2024.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Janssen Research & Development, LLC
Condition:
X-Linked Retinitis Pigmentosa
Intervention:
Biological: AAV5-hRKp.RPGR
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: October 10, 2024
Target Sample Size: 39
Countries of Recruitment:
United State...